Viz.ai integrated Cortechs.ai's NeuroQuant MS into its clinical platform to enable quantitative MRI analysis for multiple sclerosis across 2,000 U.S. hospitals. Standardized neuroimaging measurement at scale improves early detection and progression tracking, addressing a critical gap in how neurodegenerative disease is currently managed.
Key Points
- Quantitative MRI analysis embedded into clinical workflow for MS detection
- FDA-cleared technology deployed across nearly 2,000 U.S. hospitals
- Enables objective measurement of brain atrophy and disease progression
Longevity Analysis
Early and precise identification of neurodegenerative changes determines whether interventions can slow or halt progression. Standardized quantitative measurement removes subjective interpretation from clinical assessment, shifting the conversation from symptomatic response to objective biomarker tracking. When neurologists and neuroimaging specialists can measure brain volume loss, demyelination, and tissue changes with consistency across health systems, the window for neuroprotective strategies expands considerably. This infrastructure supports the broader principle that decoding what's actually happening in the nervous system—before symptoms dominate—enables clinicians to act while regenerative and protective mechanisms still respond to intervention.
Original published by LT Wire.